{
    "clinical_study": {
        "@rank": "141199", 
        "arm_group": [
            {
                "arm_group_label": "SRI 15mg", 
                "arm_group_type": "Experimental", 
                "description": "Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days."
            }, 
            {
                "arm_group_label": "MiRI 30mg", 
                "arm_group_type": "Experimental", 
                "description": "Mild Renal Impairment group orally administered 30mg DU176b once daily for 14 days."
            }, 
            {
                "arm_group_label": "Fondaparinux", 
                "arm_group_type": "Active Comparator", 
                "description": "Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and pharmacokinetics of DU-176b administered to patients with severe\n      renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b\n      administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of\n      the lower limbs.\n\n      For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of\n      the lower limbs will be compared with that of fondaparinux."
        }, 
        "brief_title": "Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Renal Insufficiency", 
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs\n\n        Exclusion Criteria:\n\n          -  Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the\n             study period\n\n          -  Patients who are at a significantly high risk for bleeding or thromboembolism\n\n          -  Patients who are receiving another antithrombotic therapy and are unable to suspend\n             the therapy\n\n          -  Patients who have evidence of hepatic function test abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857583", 
            "org_study_id": "DU176b-B-J306"
        }, 
        "intervention": [
            {
                "arm_group_label": "SRI 15mg", 
                "intervention_name": "15mg DU-176b", 
                "intervention_type": "Drug", 
                "other_name": "edoxaban"
            }, 
            {
                "arm_group_label": "MiRI 30mg", 
                "intervention_name": "30mg DU-176b", 
                "intervention_type": "Drug", 
                "other_name": "edoxaban"
            }, 
            {
                "arm_group_label": "Fondaparinux", 
                "intervention_name": "Fondaparinux", 
                "intervention_type": "Drug", 
                "other_name": "Arixtra"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fondaparinux", 
                "PENTA"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "anticoagulant", 
            "DU-176b", 
            "edoxaban", 
            "factor Xa", 
            "oral", 
            "orthopedic surgery of lower limbs", 
            "severe renal impairment"
        ], 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Asahikawa", 
                    "country": "Japan", 
                    "state": "Hokkaido Prefecture", 
                    "zip": "078-8237"
                }, 
                "name": "Toyooka Chuo Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs", 
        "overall_official": {
            "affiliation": "Osaka Koseinenkin Hospital", 
            "last_name": "Takeshi Fuji, VP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Incidence of any bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding).", 
                "measure": "Incidence of any bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Incidence of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Plasma concentration of DU-176b", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Plasma concentration of D21-2393", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence of adjudicated thromboembolic events (symptomatic Deep Vein Thrombosis [DVT], symptomatic Pulmonary Thromboembolism [PTE], Venous Thromboembolism [VTE] related deaths).", 
            "measure": "Incidence of adjudicated thromboembolic events", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}